0.00

100.00% -11.10

AgeX Therapeutics Inc (AGE)

Overview News Price History Discussions Forecast

AgeX Therapeutics Inc stock is currently priced at $0.00, with a 24-hour trading volume of 0. It has seen a -100.00% decreased in the last 24 hours and a -100.00% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $11.60 pivot point. If it approaches the $9.11 support level, significant changes may occur.

Previous Close:

$11.10

Open:

24h Volume:

Market Cap:

$27.76M

Revenue:

$73,000

Net Income/Loss:

$-14.05M

P/E Ratio:

0.00

EPS:

-0.3

Net Cash Flow:

$-7.07M

1W Performance:

-100.00%

1M Performance:

-100.00%

6M Performance:

-100.00%

1Y Performance:

-100.00%

1D Range:

$0.00

52W Range:

$0.00

$22.32

AgeX Therapeutics Inc Stock (AGE) Company Profile

Name

AgeX Therapeutics Inc

Sector

Healthcare (1197)

Industry

Biotechnology (688)

Phone

510-521-3390

Address

1010 Atlantic Avenue, Suite 102, Alameda, CA

Employee

Twitter

@agexthera

Next Earnings Date

2024-03-29

Latest SEC Filings

AGE's Discussions on Twitter

AgeX Therapeutics Inc Stock (AGE) Latest News

AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial Results

GlobeNewswire Inc.

Why IBM Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket

Benzinga

AgeX Therapeutics Inc Stock (AGE) Financials Data

AgeX Therapeutics Inc (AGE) Revenue 2024

AGE reported a revenue (TTM) of $73.00 thousand for the quarter ending September 30, 2023, a +37.74% rise year-over-year.

AgeX Therapeutics Inc (AGE) Net Income 2024

AGE net income (TTM) was -$14.05 million for the quarter ending September 30, 2023, a -41.68% decrease year-over-year.

AgeX Therapeutics Inc (AGE) Cash Flow 2024

AGE recorded a free cash flow (TTM) of -$7.07 million for the quarter ending September 30, 2023, a -12.83% decrease year-over-year.

AgeX Therapeutics Inc (AGE) Earnings per Share 2024

AGE earnings per share (TTM) was -$13.36 for the quarter ending September 30, 2023, a -46.15% decline year-over-year.

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of therapeutics for age-related degenerative diseases in the United Stated. The company is developing AGEX-BAT1 and AGEX-VASC1, which are cell-based approaches in the preclinical stage of development to correct metabolic imbalances in aging; and to restore vascular support in ischemic tissues. It is also involved in the development of AGEX-iTR1547, a drug-based formulation in preclinical development for restoring regenerative potential in various aged tissues afflicted with degenerative diseases. In addition, the company develops Renelon, a first-generation tissue regeneration product designed to promote scarless tissue repair. Further, it markets genomic interpretation algorithms; and Cytiva, including pluripotent stem cell derived heart muscle cells used in screening drugs for efficacy and safety. The company was founded in 2017 and is based in Alameda, California. AgeX Therapeutics, Inc.(AMEX:AGE) operates independently of BioTime, Inc. as of November 28, 2018.